Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer

Summary

The study aims at piloting the concept of customization of chemotherapy based on molecular markers in patients with stage IIIB (with pleural effusion) and IV with performance status ≤ 2 with pathologically proven non-small cell lung cancer (NSCLC). The study will not test or compare individual regimen but rather it will test the approach of customization concept as a whole. The results of this pilot study will help in designing more definitive trials in our patient population.

Timeline

Start

2010-05

Primary completion

2013-05

Completion

2013-05

Outcome

Outcome not reported

Stopped (Enrollment): “slow accrual rate”

Drugs

Indications